세계의 인간화 마우스 및 래트 모델 시장

Global Humanized Mouse and Rat Model Market to Reach US$219.4 Million by 2030

The global market for Humanized Mouse and Rat Model estimated at US$143.5 Million in the year 2024, is expected to reach US$219.4 Million by 2030, growing at a CAGR of 7.3% over the analysis period 2024-2030. Oncology Application, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$74.5 Million by the end of the analysis period. Growth in the Immunology & Infectious Diseases Application segment is estimated at 6.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$38.5 Million While China is Forecast to Grow at 10.8% CAGR

The Humanized Mouse and Rat Model market in the U.S. is estimated at US$38.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$47.3 Million by the year 2030 trailing a CAGR of 10.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.0% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.6% CAGR.

Global Humanized Mouse and Rat Model Market - Key Trends and Drivers Summarized

Are Humanized Mouse and Rat Models the Key to Breakthroughs in Biomedical Research and Precision Medicine?

Humanized mouse and rat models have revolutionized preclinical research, but why are they so essential for advancing drug development, immunology studies, and precision medicine? Humanized models refer to laboratory mice or rats that have been genetically modified or engrafted with human cells, tissues, or genes, enabling them to mimic human biological systems more closely. These models provide researchers with a powerful tool for studying human diseases, immune responses, cancer biology, and evaluating the safety and efficacy of new treatments before they proceed to clinical trials.

The significance of humanized mouse and rat models lies in their ability to simulate human-specific responses that cannot be observed in conventional animal models. By using humanized models, researchers can study human immune function, infection mechanisms, and cancer progression with greater accuracy, bridging the gap between animal studies and human clinical trials. This improves the likelihood that experimental therapies and vaccines will succeed in humans. As precision medicine and immunotherapy continue to gain prominence, humanized models are playing a crucial role in advancing personalized healthcare and accelerating the development of life-saving treatments.

How Has Technology Advanced Humanized Mouse and Rat Models?

Technological advancements have significantly improved the development, functionality, and application of humanized mouse and rat models, making them more versatile and representative of human biology. One of the most important advancements is the ability to engraft human immune cells or tissues into immunodeficient mice. These mice lack functional immune systems, allowing human cells to survive and proliferate. Humanized immune system (HIS) mice are often used to study human immune responses to infections, autoimmune diseases, and cancer. For example, researchers can observe how human immune cells react to viral infections like HIV or COVID-19, gaining critical insights into the pathogenesis of these diseases and identifying potential therapeutic targets.

The use of gene editing technologies, such as CRISPR-Cas9, has further advanced the development of humanized mouse and rat models. With CRISPR, researchers can precisely insert human genes into the genomes of mice or rats, creating models that express human proteins or receptors. This has been particularly useful in cancer research, where scientists can create humanized models that express human cancer-driving mutations or tumor suppressor genes. These models allow for the testing of targeted therapies, such as monoclonal antibodies or small-molecule inhibitors, in a system that closely mirrors human cancer biology.

Another major breakthrough is the development of humanized liver models. In these models, mice are engrafted with human hepatocytes (liver cells), making them ideal for studying human-specific drug metabolism, liver diseases, and toxicology. Humanized liver mice are invaluable for assessing how new drugs are metabolized in the human liver, helping to predict potential side effects or toxicities that might not be detected in traditional animal models. These models are also used to study hepatitis infections, offering a better understanding of how viral infections affect human liver function and aiding in the development of antiviral treatments.

Advances in human stem cell research have also contributed to the improvement of humanized models. Human pluripotent stem cells (hPSCs) can be differentiated into various human cell types, including immune cells, neurons, and pancreatic cells, which can then be engrafted into mice. These models are used to study human-specific biological processes, such as neurodegeneration in diseases like Alzheimer’s or Parkinson’s, diabetes, or even cardiovascular diseases. For example, humanized models with human neurons or glial cells enable researchers to investigate how these cells behave in a living organism, providing critical insights into neurological diseases and potential treatments.

The development of "multi-tissue" humanized models is another significant advancement. These models are engrafted with several types of human tissues or organs, creating a more complete human biological environment. Multi-tissue humanized models allow researchers to study complex diseases, such as cancer metastasis, where interactions between different tissues (e.g., tumors and immune cells) are key to disease progression. This is particularly important for studying therapies that target multiple organs or systems, such as immunotherapies for cancer or treatments for autoimmune disorders.

Improved animal husbandry and breeding techniques have made it possible to produce humanized models more consistently and at scale. These techniques have streamlined the process of creating humanized mice and rats, ensuring that researchers have access to high-quality, reproducible models for their studies. In addition, advances in cryopreservation and transplantation techniques have made it easier to engraft human cells or tissues into animals, improving the overall success rate of creating viable humanized models.

Why Are Humanized Mouse and Rat Models Critical for Drug Development and Precision Medicine?

Humanized mouse and rat models are critical for drug development and precision medicine because they provide a more accurate representation of human biology, allowing for better predictions of how drugs will behave in humans. Traditional animal models, while useful, often fail to mimic human-specific responses to drugs, diseases, and therapies. Humanized models bridge this gap by incorporating human cells, genes, or tissues into animal systems, enabling researchers to study human disease mechanisms and drug effects in a more relevant context.

In drug development, humanized models are particularly important for preclinical testing of new therapies. Before a drug can be tested in human clinical trials, it must undergo extensive testing in animal models to ensure its safety and efficacy. Humanized models allow researchers to observe how human cells or tissues react to potential therapies, reducing the risk of unexpected side effects or failures in human trials. For example, in oncology, humanized models can be used to test how human tumors respond to chemotherapy, targeted therapies, or immunotherapies like checkpoint inhibitors. By providing a more realistic model of how human cancer cells behave, these studies can help identify which therapies are most likely to be effective in clinical settings.

Humanized immune system (HIS) mice are also invaluable in immunotherapy research. Immunotherapies, such as CAR T-cell therapy or immune checkpoint inhibitors, rely on the patient’s immune system to attack cancer cells. Testing these therapies in traditional animal models is challenging because mouse immune systems differ significantly from human immune systems. Humanized immune models, however, allow researchers to test immunotherapies on human immune cells in vivo, providing critical insights into how these therapies will perform in patients. This is particularly important for precision medicine, where treatments are tailored to individual patients based on their unique genetic and immunological profiles.

In addition to cancer research, humanized models are essential for studying infectious diseases. HIS mice are commonly used to investigate how human immune cells respond to infections like HIV, hepatitis, or COVID-19. By providing a model that mimics human immune responses, these studies help identify new therapeutic targets and test vaccines or antiviral drugs in a more accurate setting. For example, humanized mice were used in the development and testing of antiviral treatments and vaccines for COVID-19, playing a crucial role in understanding the virus’s impact on human cells and immune responses.

Humanized liver models are particularly important for drug metabolism and toxicology studies. The human liver plays a central role in metabolizing drugs, and animal models often do not metabolize drugs in the same way as humans. Humanized liver mice allow researchers to study how new drugs are processed in the human liver, helping to identify potential toxicities or adverse effects before they are tested in human clinical trials. This reduces the likelihood of drug failures in late-stage trials, saving time and resources for pharmaceutical companies.

Humanized models are also key to advancing personalized and precision medicine. In precision medicine, treatments are tailored to an individual’s specific genetic makeup, environment, and lifestyle. Humanized models, particularly those engrafted with patient-specific cells or tissues, enable researchers to test how an individual’s unique biology responds to specific treatments. This approach is especially valuable in oncology, where therapies like targeted treatments or immunotherapies are designed based on a patient’s tumor genetics or immune profile. By using humanized models to test these personalized therapies in preclinical studies, researchers can optimize treatments for individual patients and improve clinical outcomes.

What Factors Are Driving the Growth of the Humanized Mouse and Rat Model Market?

Several factors are driving the rapid growth of the humanized mouse and rat model market, including the increasing demand for more accurate preclinical models in drug development, advancements in gene editing technologies, and the rise of personalized medicine. One of the primary drivers is the need for more human-relevant models in drug discovery and development. Traditional animal models often fail to predict human responses accurately, leading to high failure rates in clinical trials. Humanized models offer a more reliable platform for testing the efficacy and safety of new drugs, reducing the likelihood of late-stage failures and improving the overall success rate of drug development programs.

The rise of immunotherapies and targeted cancer treatments is another significant driver of the market. As immunotherapies become more widely used in treating cancer and other diseases, there is a growing need for models that can accurately replicate human immune responses. Humanized immune system (HIS) mice provide a crucial tool for testing these therapies, helping researchers optimize treatments and understand their mechanisms of action in a human-like immune environment. This is especially important as more pharmaceutical companies focus on developing personalized cancer treatments based on a patient’s specific genetic or immunological profile.

Advancements in gene editing technologies, such as CRISPR-Cas9, have made it easier to create genetically modified humanized models. With CRISPR, researchers can precisely insert human genes into mouse or rat genomes, enabling the creation of highly specific models for studying diseases like cancer, Alzheimer’s, and autoimmune disorders. These advancements have significantly increased the versatility and applicability of humanized models, making them an essential tool for researchers in a wide range of biomedical fields.

The growing interest in precision medicine is also driving demand for humanized models. Precision medicine aims to tailor treatments based on individual genetic and biological factors, and humanized models allow researchers to test therapies in a way that reflects human variability. By using humanized models engrafted with patient-specific cells or tissues, researchers can study how a particular patient’s biology will respond to different treatments, improving the chances of successful outcomes in clinical settings.

The increasing prevalence of infectious diseases, particularly viral infections like HIV, hepatitis, and more recently, COVID-19, is further driving the growth of the humanized model market. These models are used to study how human immune cells respond to viral infections and to test potential vaccines or antiviral drugs. During the COVID-19 pandemic, humanized models played a critical role in understanding the virus’s effects on human cells and testing vaccine candidates. As the global focus on infectious disease research continues to grow, humanized models will remain essential for developing effective treatments and vaccines.

Regulatory support and government initiatives are also contributing to market growth. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are increasingly recognizing the value of humanized models in preclinical studies, particularly for testing biologics, immunotherapies, and personalized treatments. This regulatory support is encouraging pharmaceutical companies and research institutions to invest in humanized model development, further expanding the market.

With advancements in gene editing, the rise of immunotherapies, and the growing demand for precision medicine, the humanized mouse and rat model market is poised for significant growth. As researchers continue to seek more human-relevant models for drug development, disease research, and personalized healthcare, humanized models will remain a crucial tool for bridging the gap between preclinical studies and successful human treatments.

SCOPE OF STUDY:

The report analyzes the Humanized Mouse and Rat Model market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Humanized Mouse Models, Humanized Rat Models); Application (Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis, Other Applications); End-Use (Academic & Research Institutions, Pharma & Biotech Companies, Contract Research Organizations (CROs))

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• Axenis S.A.S.
• Charles River Laboratories International, Inc.
• Crown Bioscience, Inc.
• Genoway S.A.
• Harbour Antibodies BV
• Hera BioLabs
• inGenious Targeting Laboratory, Inc.
• Taconic Biosciences, Inc.
• The Jackson Laboratory
• Trans Genic, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
  • Global Economic Update
  • Humanized Mouse and Rat Model - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Expansion of Immuno-oncology and Cancer Research Spurs Adoption of Humanized Animal Models
  • Growth in Use of Humanized Models for Studying Immune Response Expands Addressable Market
  • Growth in Use of Humanized Mouse Models for Infectious Disease Research Expands Market Opportunities
  • Growth in Demand for Humanized Models in Antibody and Vaccine Development Fuels Adoption
  • Role of Humanized Models in Supporting Gene Therapy and Regenerative Medicine Strengthens Market Demand
  • Increasing Focus on Creating Humanized Models for Neurodegenerative Diseases Expands Adoption
  • Growth in Use of Humanized Models in HIV and Hepatitis Research Strengthens Market Opportunities
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 2: World 6-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 3: World Recent Past, Current & Future Analysis for Immunology & Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 4: World 6-Year Perspective for Immunology & Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Neuroscience by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 6: World 6-Year Perspective for Neuroscience by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Hematopoesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 8: World 6-Year Perspective for Hematopoesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 9: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 10: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Humanized Mouse Models by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 12: World 6-Year Perspective for Humanized Mouse Models by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Humanized Rat Models by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 14: World 6-Year Perspective for Humanized Rat Models by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 15: World Recent Past, Current & Future Analysis for Academic & Research Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 16: World 6-Year Perspective for Academic & Research Institutions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 18: World 6-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Contract Research Organizations (CROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 20: World 6-Year Perspective for Contract Research Organizations (CROs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 21: World Humanized Mouse and Rat Model Market Analysis of Annual Sales in US$ for Years 2015 through 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 23: World 6-Year Perspective for Humanized Mouse and Rat Model by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Humanized Mouse and Rat Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 24: USA Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 25: USA 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 26: USA Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 28: USA Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 29: USA 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
• CANADA
  • TABLE 30: Canada Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 31: Canada 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Canada 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 34: Canada Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 35: Canada 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
• JAPAN
  • Humanized Mouse and Rat Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 36: Japan Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 37: Japan 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Japan 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 40: Japan Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 41: Japan 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
• CHINA
  • Humanized Mouse and Rat Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 42: China Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 43: China 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 44: China Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 45: China 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 46: China Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 47: China 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
• EUROPE
  • Humanized Mouse and Rat Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 48: Europe Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 49: Europe 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Europe 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 52: Europe Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 53: Europe 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
  • TABLE 54: Europe Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 55: Europe 6-Year Perspective for Humanized Mouse and Rat Model by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
• FRANCE
  • Humanized Mouse and Rat Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 56: France Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 57: France 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 58: France Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 59: France 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 60: France Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 61: France 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
• GERMANY
  • Humanized Mouse and Rat Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 62: Germany Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Germany 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 64: Germany Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 65: Germany 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 66: Germany Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 67: Germany 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
• ITALY
  • TABLE 68: Italy Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Italy 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 70: Italy Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 71: Italy 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 72: Italy Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 73: Italy 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
• UNITED KINGDOM
  • Humanized Mouse and Rat Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 74: UK Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 75: UK 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 76: UK Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 77: UK 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 78: UK Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 79: UK 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
• SPAIN
  • TABLE 80: Spain Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Spain 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 82: Spain Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 83: Spain 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 84: Spain Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 85: Spain 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
• RUSSIA
  • TABLE 86: Russia Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Russia 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 88: Russia Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 89: Russia 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 90: Russia Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 91: Russia 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Rest of Europe 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 94: Rest of Europe Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 95: Rest of Europe 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 96: Rest of Europe Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 97: Rest of Europe 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
• ASIA-PACIFIC
  • Humanized Mouse and Rat Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Asia-Pacific 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 100: Asia-Pacific Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 101: Asia-Pacific 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 102: Asia-Pacific Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 103: Asia-Pacific 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
  • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 105: Asia-Pacific 6-Year Perspective for Humanized Mouse and Rat Model by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
• AUSTRALIA
  • Humanized Mouse and Rat Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 106: Australia Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 107: Australia 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 108: Australia Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 109: Australia 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 110: Australia Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Australia 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
• INDIA
  • Humanized Mouse and Rat Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 112: India Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 113: India 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 114: India Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 115: India 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 116: India Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 117: India 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
• SOUTH KOREA
  • TABLE 118: South Korea Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 119: South Korea 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 120: South Korea Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 121: South Korea 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 122: South Korea Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 123: South Korea 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 124: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 125: Rest of Asia-Pacific 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 126: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 127: Rest of Asia-Pacific 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Rest of Asia-Pacific 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
• LATIN AMERICA
  • Humanized Mouse and Rat Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 130: Latin America Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 131: Latin America 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 132: Latin America Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 133: Latin America 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 134: Latin America Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Latin America 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
  • TABLE 136: Latin America Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 137: Latin America 6-Year Perspective for Humanized Mouse and Rat Model by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
• ARGENTINA
  • TABLE 138: Argentina Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 139: Argentina 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 140: Argentina Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Argentina 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 142: Argentina Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 143: Argentina 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
• BRAZIL
  • TABLE 144: Brazil Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 145: Brazil 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 146: Brazil Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Brazil 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 148: Brazil Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 149: Brazil 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
• MEXICO
  • TABLE 150: Mexico Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 151: Mexico 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 152: Mexico Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Mexico 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 154: Mexico Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 155: Mexico 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 156: Rest of Latin America Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 157: Rest of Latin America 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Rest of Latin America 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 160: Rest of Latin America Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 161: Rest of Latin America 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
• MIDDLE EAST
  • Humanized Mouse and Rat Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 162: Middle East Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 163: Middle East 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 164: Middle East Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Middle East 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 166: Middle East Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 167: Middle East 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
  • TABLE 168: Middle East Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 169: Middle East 6-Year Perspective for Humanized Mouse and Rat Model by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
• IRAN
  • TABLE 170: Iran Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Iran 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 172: Iran Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 173: Iran 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 174: Iran Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 175: Iran 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
• ISRAEL
  • TABLE 176: Israel Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Israel 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 178: Israel Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 179: Israel 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 180: Israel Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 181: Israel 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
• SAUDI ARABIA
  • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Saudi Arabia 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 184: Saudi Arabia Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 185: Saudi Arabia 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 186: Saudi Arabia Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 187: Saudi Arabia 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 188: UAE Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 189: UAE 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 190: UAE Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 191: UAE 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 192: UAE Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 193: UAE 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Middle East 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 196: Rest of Middle East Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 197: Rest of Middle East 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 198: Rest of Middle East Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 199: Rest of Middle East 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030
• AFRICA
  • Humanized Mouse and Rat Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 200: Africa Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Application - Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Africa 6-Year Perspective for Humanized Mouse and Rat Model by Application - Percentage Breakdown of Value Sales for Oncology, Immunology & Infectious Diseases, Neuroscience, Hematopoesis and Other Applications for the Years 2025 & 2030
  • TABLE 202: Africa Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by Type - Humanized Mouse Models and Humanized Rat Models - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 203: Africa 6-Year Perspective for Humanized Mouse and Rat Model by Type - Percentage Breakdown of Value Sales for Humanized Mouse Models and Humanized Rat Models for the Years 2025 & 2030
  • TABLE 204: Africa Recent Past, Current & Future Analysis for Humanized Mouse and Rat Model by End-Use - Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 205: Africa 6-Year Perspective for Humanized Mouse and Rat Model by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutions, Pharma & Biotech Companies and Contract Research Organizations (CROs) for the Years 2025 & 2030

IV. COMPETITION